Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 2,911,999 | 2,771,900 | 2,645,600 | 2,690,600 | 2,517,700 |
| Cost of Goods | 423,400 | 392,600 | 371,900 | 342,600 | 368,000 |
| Gross Profit | 2,488,600 | 2,379,300 | 2,273,700 | 2,348,000 | 2,149,700 |
| Operating Expenses | 1,463,001 | 1,263,600 | 5,789,300 | 1,209,100 | 1,162,200 |
| Operating Income | 1,026,000 | 1,116,300 | -3,514,700 | 1,139,500 | 988,500 |
| Interest Expense | 2,800 | 7,500 | 9,900 | 10,400 | 10,600 |
| Other Income | 113,300 | 115,300 | 133,400 | 150,000 | 169,700 |
| Pre-tax Income | 1,136,500 | 1,224,100 | -3,391,200 | 1,279,100 | 1,147,600 |
| Income Tax | 223,500 | 178,700 | 202,400 | 179,500 | 178,800 |
| Net Income Continuous | 913,000 | 1,045,400 | -3,593,600 | 1,099,600 | 968,800 |
| Net Income | $913,000 | $1,045,400 | $-3,593,600 | $1,099,600 | $968,800 |
| EPS Basic Total Ops | 3.53 | 4.05 | -13.92 | 4.26 | 3.77 |
| EPS Basic Continuous Ops | 3.54 | 4.05 | -13.92 | 4.26 | 3.76 |
| EPS Diluted Total Ops | 3.62 | 4.01 | -13.92 | 4.21 | 3.71 |
| EPS Diluted Continuous Ops | 3.63 | 4.01 | -13.92 | 4.21 | 3.72 |
| EPS Diluted Before Non-Recurring Items | 3.54 | 4.04 | -13.27 | N/A | N/A |
| EBITDA(a) | $1,072,498 | $1,169,500 | $-3,460,700 | $1,193,000 | $1,047,500 |